METHODS OF DETERMINING A TREATMENT PROTOCOL FOR AND/OR A PROGNOSIS OF A PATIENT'S RECOVERY FROM A BRAIN INJURY RESULTING FROM A HYPOXIC EVENT

• US 20140094386A1
• Filed: 04/12/2012
• Published: 04/03/2014
• Est. Priority Date: 04/12/2011
• Status: Abandoned Application

• Current Assignee: Quanterix Corporation
• Original Assignee: Quanterix Corporation
• Inventors: Song, Linan, Wilson, David
• Application Number:
  US14/111,331
• Publication Number:
  US 20140094386A1
• Time in Patent Office: Days
• US Class Current: 506/9
• CPC Class Codes: G01N 2333/4709 Amyloid plaque core protein
• CPC Class Codes: G01N 2800/28 Neurological disorders
• CPC Class Codes: G01N 2800/2871 Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/5306 Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

The present invention, in some embodiments, generally relates to methods of determining a treatment protocol for and/or a prognosis of a patient'"'"'s recovery from a brain injury resulting from a hypoxic event. In some embodiments, methods are provided for determining a measure of the concentration of beta-amyloid peptide in a patient sample containing or suspected of containing beta-amyloid peptide.

Claims

1. A method for determining a measure of the concentration of beta-amyloid peptide in a patient sample containing or suspected of containing beta-amyloid peptide, comprising:

performing an assay to determine a measure of the concentration of beta-amyloid peptide in the sample, wherein the limit of detection of beta-amyloid peptide of the assay is less than about 0.2 pg/mL.

2. The method of claim 1, wherein the beta-amyloid peptide is beta-amyloid (1-42).

3. The method of claim 1, wherein the patient has had a hypoxic event or a suspected hypoxic event.

4. The method of claim 1, wherein the sample is a bodily fluid.

5. The method of claim 4, wherein the bodily fluid is blood or a blood component.

6. The method of claim 4, wherein the bodily fluid is CSF.

7. The method of claim 5, wherein the blood component is plasma or serum.

8. The method of claim 1, wherein the measure of the concentration of beta-amyloid peptide is determined in a plurality of samples taken from the patient over a period of time.

9. The method of claim 8, wherein the plurality of samples are collected within 96 hours after the patient has experienced a hypoxic event or suspected hypoxic event.

10. A method of determining a patient'"'"'s prognosis for recovery from, and/or determining a course of treatment for, a brain injury following a hypoxic event, wherein the prognosis and/or the course of treatment is based at least in part on the measure of the concentration of beta-amyloid peptide determined in the patient sample according to the method of claim 1.

11. A method for determining a patient'"'"'s prognosis for recovery from, and/or determining a course of treatment for, a brain injury following a hypoxic event or suspected hypoxic event, comprising:

performing an assay on a plurality of samples obtained from the patient following the event to determine a measure of the concentration of at least one biomarker in each sample, wherein the concentration of the biomarker in each sample is less than about 100 pg/mL, and wherein the assay has a limit of quantification of less than about 10 pg/mL; and

determining a prognosis of the patient'"'"'s recovery and/or determining a course of treatment based at least in part on the measured concentration of the at least one biomarker measured in each sample.

23. The method of claim 11, wherein the biomarker is a beta-amyloid peptide.

24. The method of claim 11, wherein the beta-amyloid peptide is beta-amyloid (1-42).

25. The method of claim 11, wherein the hypoxic event is caused by cardiac arrest.

26. The method of claim 11, wherein the hypoxic event is caused by stroke.

27. The method of claim 11, wherein the hypoxic event is caused by an ischemic event.

28. The method of claim 11, wherein the hypoxic event is caused by a thrombosis.

29. The method of claim 11, wherein the hypoxic event is caused by arterial embolism.

30. The method of claim 11, wherein the hypoxic event is caused by a hemorrhage.

12-14. -14. (canceled)

15. A method of determining a treatment protocol for, and/or a prognosis of a patient'"'"'s recovery from, a brain injury resulting from a hypoxic event, comprising:

performing an assay to determine a measure of the concentration of only a first biomarker present in a plurality of samples obtained from the patient following the event, wherein the concentration of the first biomarker is less than about 100 pg/mL, and wherein the assay has a limit of quantification of less than about 10 pg/mL; and

determining a prognosis of the patient'"'"'s recovery from the brain injury and/or a method of treatment based at least in part on the measured concentration of the first biomarker in the plurality of samples.

16-22. -22. (canceled)

31-99. -99. (canceled)